How Much Does FDA Clearance Cost? Data for Founders
FDA clearance cost breaks into five categories that have no public list price: the FDA user fee, regulatory consultant fees, testing and validation costs, quality system setup, and submission preparation. Your pathway — 510(k), De Novo, or PMA — changes how large each category gets relative to the others, not whether it applies to you.
Quick Answer: FDA clearance cost is the sum of five variable line items — the FDA user fee, regulatory consultant/RA fees, testing and validation costs, quality system setup, and submission preparation — plus recurring costs once you're cleared. There is no reliable single "FDA clearance costs $X" figure. Real numbers come from FDA's current fee schedule and quotes from your own regulatory consultant, testing lab, and quality system provider, scoped to your specific device, classification, and pathway.
You will find FDA clearance cost figures published all over the internet, usually presented as a single confident number like "a 510(k) costs $X." Treat every one of them with suspicion, including any number you might see elsewhere on this site. FDA's own user fees change every fiscal year and depend on whether you qualify for the small business rate; consultant, testing, and quality-system costs depend on your device's classification, the standards it has to meet, and how much work you do in-house versus outsource. A number pulled from a general article is more likely to anchor your budget wrong than to help you plan it. This article teaches the cost and timeline categories to price, and where to get real figures for each, not a table of numbers to copy. If you haven't yet confirmed your device needs FDA clearance at all, start with validating a medical device startup idea, which walks through the clinical, regulatory, and reimbursement gates before cost planning is even the right next question.
What Actually Makes Up FDA Clearance Cost
FDA clearance cost is the sum of five buckets — regulatory/FDA fees, consulting, testing and validation, quality system, and submission preparation — each priced by a different authority or vendor, not looked up in one table. The table below turns each bucket into a checklist of line items to price, deliberately leaving the dollar figures out for you to fill in from your own quotes.
| Cost line item | Bucket | Fixed or variable | What drives it | Where to get a real number |
|---|---|---|---|---|
| FDA user fee (MDUFA) | Regulatory / FDA fees | Fixed per submission type, reduced for qualifying small businesses | Which pathway you file — 510(k), De Novo, or PMA — and your small-business-fee eligibility | FDA's current-fiscal-year MDUFA fee schedule, published on fda.gov |
| Regulatory consultant / RA specialist | Consulting | Variable — hourly or project-based | Device complexity, how novel the classification is, how much you handle in-house | A regulatory consulting firm scoped to your specific device and pathway |
| Nonclinical / bench testing (biocompatibility, electrical safety, EMC, sterilization, etc.) | Testing & validation | Variable | Which recognized standards apply to your device's type and materials | An accredited testing lab quote against the specific standards your device must meet |
| Clinical data, if required | Testing & validation | Highly variable — sometimes zero, sometimes the largest line item | Whether your pathway and classification require original clinical evidence, sample size, number of sites | A CRO quote, obtained only after your regulatory strategy confirms a clinical study is actually needed |
| Quality management system setup | Quality system | Mixed — upfront build plus recurring maintenance | Whether you build in-house or use a consultant/eQMS platform, whether you already hold ISO 13485 certification | A QMS consultant or eQMS vendor quote |
| Submission preparation and compilation | Consulting | Often bundled into consultant fees, sometimes billed separately | Submission length and complexity, whether your device is novel enough to need extra justification | The same regulatory consultant, scoped explicitly to authoring the submission |
| Post-clearance costs (establishment registration, device listing, ongoing audits) | Ongoing / post-market | Recurring annual | Number of facilities, whether you keep manufacturing, audit frequency your QMS requires | FDA's annual establishment registration fee schedule and your QMS auditor |
Two of these buckets behave like a toll you pay once. The FDA user fee and most submission-preparation work are roughly fixed per filing, so they're the easiest line items to quote accurately early. The rest behave more like a cost that scales with how novel and how tightly regulated your device turns out to be — testing, consulting, and clinical evidence can each expand quietly if your classification is more complex than you assumed going in. Budget the fixed items first, then treat every variable line as a range to narrow with real quotes, not a number to lock in before you have one.
How Long FDA Clearance Takes, By Pathway
FDA clearance timelines are built from review cycles, not one continuous countdown. FDA's review clock pauses every time it issues an Additional Information (AI) request and doesn't resume until you respond, which is why the calendar time a submission actually takes tends to run longer than the published review-goal period for a single pass — most first submissions go through more than one cycle.
| Pathway | Typical review-cycle structure | What extends the timeline | Where to get a current estimate |
|---|---|---|---|
| 510(k) | Comparative review against your named predicate; a single AI cycle is common, multiple cycles happen when the equivalence argument is weak | Incomplete submissions, a shaky predicate argument, requests for additional bench testing | FDA's current MDUFA performance-goal documentation, plus your consultant's estimate based on similar recent filings |
| De Novo | Broader review scope since there's no predicate to lean on; FDA is also evaluating the special controls you're proposing for a brand-new device category | Negotiating novel special controls, no comparator data to fall back on if a reviewer raises a question | Same MDUFA performance-goal documentation, plus a consultant experienced with recent De Novo grants in your device area |
| PMA (for context) | The most extensive review of the three, generally involving deeper clinical-evidence review and sometimes an advisory panel | The clinical study itself, which sits outside the FDA review clock entirely, plus facility inspection scheduling | FDA's PMA-specific guidance and a consultant who has run a PMA submission before |
Notice that pathway alone doesn't set your timeline — testing scope and how much original evidence work you have to do inside that pathway matter just as much. If you haven't settled which pathway even applies to your device, 510(k) vs. De Novo walks through the predicate-availability question that decides between them, which is the fork that determines how much of your evidence plan is comparative versus original, and therefore how many review cycles you should realistically plan for.
Where Device Startups Overspend on FDA Clearance
Most FDA clearance budgets don't blow up on the line items founders expect. They blow up on decisions made before a consultant is even in the room.
- Skipping the pre-submission meeting to save time. A pre-submission conversation with FDA is generally cheaper and faster than absorbing an extra Additional Information cycle later, but founders under time pressure routinely skip it.
- Under-scoping consultant involvement early, then paying rush rates later. A weak first submission that comes back with an AI request, or a "not substantially equivalent" finding, tends to cost more to fix than it would have cost to scope correctly the first time.
- Building manufacturing and quality-system processes before the pathway is confirmed. Guessing wrong about classification means redoing validation work once the actual pathway and applicable standards are settled.
- Running a clinical study broader than the classification requires. This happens when nobody scopes the minimum viable evidence package with a regulatory strategist before designing the study.
- Choosing a testing lab on price alone. A lab that isn't accredited for, or experienced with, the specific standard your device needs can produce results a reviewer rejects, forcing a repeat at a second lab.
- Treating clearance as the finish line. Establishment registration, device listing, and ongoing quality-system maintenance keep accruing after you're cleared — a budget that stops at the submission fee is incomplete.
Every pattern above shares a root cause: money spent to save time on a step that later costs more time and money to redo. The fix isn't a bigger budget — it's sequencing pathway confirmation and evidence scoping before committing testing or manufacturing dollars, the same test-the-risky-assumption-before-you-build-around-it discipline that governs the rest of your validation work, covered in full in the complete guide to startup idea validation.
Methodology and Source Notes
This article deliberately contains no dollar figures or day counts for FDA clearance, because any number specific enough to be useful to you would also be specific enough to be wrong for your device.
FDA's own MDUFA fee schedule resets every fiscal year and carries separate standard and small-business rates, so a figure printed in an article is stale the moment FDA issues its next update. Testing, consulting, and clinical costs are quoted per-device by the vendors who perform the work, not published as an industry list price — no regulatory database maintains a reliable public average across the range of device types and testing scopes that exist. The methodology behind this piece is to teach the cost and timeline categories as a durable framework, then point you to the primary source for each one: FDA's current fee schedule and guidance documents on fda.gov for the user fee itself, an accredited testing lab for validation costs, a regulatory consulting firm for consulting and submission-prep costs, and — once a submission strategy exists — a CRO for any clinical work. Treat any article, including this one, that states a specific dollar figure or month count for FDA clearance as either already stale or scoped to a device that isn't yours.
Key Takeaways
- Price five categories, not one number. FDA user fee, regulatory consulting, testing and validation, quality system, and submission preparation each need their own quote.
- The FDA fee is the only line item with a public number, and even that changes every fiscal year and depends on small-business eligibility — confirm it against FDA's current schedule rather than an old article.
- Fixed and variable costs behave differently. The FDA fee and most submission-prep work are roughly fixed per filing; testing, consulting, and clinical evidence scale with how novel and tightly regulated your device turns out to be.
- Timelines are built from review cycles, not a single countdown. Additional Information requests pause FDA's review clock, and most first submissions go through more than one cycle.
- Most overspending happens before the consultant is even hired. Skipped pre-submission meetings, over-scoped clinical studies, and premature manufacturing builds cost more to redo than to do right the first time.
- Real quotes beat published ranges every time. Any specific number this article or any other publishes will be a general average at best and wrong for your device at worst — start pricing your own five categories now, not after the classification question is settled.
Frequently Asked Questions
How much does FDA 510(k) clearance cost?
There's no reliable single figure. It depends on FDA's current user fee — which differs for standard filers and qualifying small businesses — how much testing your device needs against applicable recognized standards, and how much regulatory consulting work you require. Get FDA's current fee schedule from fda.gov and a scoped quote from a regulatory consultant before budgeting a specific number.
Is De Novo or PMA more expensive than a 510(k)?
Generally yes, because both typically involve more original evidence work than a 510(k) backed by a strong predicate — you can't lean on comparative data against an existing cleared device the way a 510(k) filer can. But turning that into a specific dollar comparison isn't something to take as settled fact; the actual gap depends on your device's testing scope and clinical evidence needs, which only a consultant scoped to your product can quote.
How long does FDA clearance take?
Longer than the single number most articles quote, in most cases, because FDA's review clock pauses during Additional Information request cycles and most first submissions receive at least one round of them. Realistic timeline planning means budgeting for more than one review cycle, not the headline review-goal period for a single pass — confirm current performance-goal data with FDA or your regulatory consultant.
Can I reduce FDA clearance costs by doing more of the work myself?
Some of it, yes — founders with regulatory or scientific backgrounds sometimes handle submission drafting or predicate research in-house rather than paying a consultant for it. But cutting corners on testing against required standards, on pre-submission strategy, or on quality system setup tends to create rework that costs more than the consulting fee it avoided. The highest-leverage place to spend consulting dollars early is usually pathway and evidence-scoping strategy, not submission paperwork.